Mounjaro

Mounjaro is administered once a week as a subcutaneous injection, typically in the thigh, abdomen, or upper arm. It can be taken at any time of the day, with or without food. Aim to administer the injection on the same day each week. Always follow your doctor's instructions regarding the correct dosage. If you are unsure how to inject, consult your doctor or pharmacist for guidance. If you miss a dose, take it as soon as possible if fewer than 4 days have passed. If more than 4 days have elapsed, skip the missed dose and continue with your regular schedule.

The manufacturer of Mounjaro is:

Eli Lilly and Company
Indianapolis, IN 46285
USA

The active ingredient in Mounjaro is tirzepatide. Depending on your doctor's instructions, each injection contains between 2.5 mg and 15 mg of tirzepatide. The excipients include sodium phosphate, sodium chloride, and water for injections.

As with any medication, Mounjaro may cause side effects. Common side effects include nausea, diarrhoea, decreased appetite, vomiting, and constipation. These symptoms often subside as your body adjusts to the medication. Occasionally, you may experience abdominal pain, indigestion, or flatulence. In rare cases, pancreatitis (inflammation of the pancreas) or a severe allergic reaction may occur. Seek medical attention immediately if you experience severe abdominal pain, swelling, or difficulty breathing.

Mounjaro is suitable for most individuals with overweight and/or type 2 diabetes. However, it is not appropriate if you are allergic to tirzepatide or any of the excipients, if you have type 1 diabetes, or if you have diabetic ketoacidosis. Consult your doctor if you have severe stomach or intestinal issues or a history of pancreatitis. Extra caution is advised if you have erectile dysfunction in combination with diabetes, as fluctuations in blood sugar levels can have an impact. Do not use Mounjaro if you are pregnant or planning to become pregnant. Discontinue its use at least 2 months before attempting to conceive. Exercise caution when using insulin or sulfonylureas (such as gliclazide), as these increase the risk of low blood sugar.